Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections

A. N. Poindexter, M. Ritter, S. Faro, M. A. Castellano, L. O. Gentry, M. Ismail, R. A. Knuppel, A. K. Kreutner, E. J. Lamb, J. L. LeFrock, R. D. Miller, F. Naftolin, Richard L Sweet

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a multicenter trial involving 11 centers, 160 women were enrolled to evaluate the safety and effectiveness of 1 or 2 gm of cefotetan administered every 12 hours in the treatment of obstetric and gynecologic infections. The 133 evaluable patients generally were under 25 years of age, were nonwhite, and had hospital acquired endometritis or pelvic inflammatory disease caused by both aerobic and anaerobic bacteria. Escherichia coli, Neisseria gonorrhoeae, group D streptrococci, Bacteroides sp., and Peptococcus sp. were among the most frequently isolated pathogens. The patients were treated for a mean of 5.6 ± 1.6 days and received a total dose of 19.27 gm. The signs and symptoms of infection were cleared or improved in 93% of the 133 patients evaluable for clinical response. Of the 116 evaluated bacteriologically, 95% had a satisfactory or presumed satisfactory response; only six patients (5%) were considered to be bacteriologic failures. Differences in the results of several clinical laboratory tests performed before and after treatment were statistically, but not clinically, significant (p < 0.05). Safety was evaluated in the 158 patients who received cefotetan, and only four (3%) had adverse reactions considered related to the drug. Cefotetan was clearly effective and produced no untoward reactions in these women with obstetric and gynecologic infections caused by both aerobic and anaerobic organisms when administered at 1 or 2 gm every 12 hours.

Original languageEnglish (US)
Pages (from-to)717-721
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume158
Issue number3 II SUPPL.
StatePublished - 1988
Externally publishedYes

Fingerprint

Cefotetan
Obstetrics
Infection
Peptococcus
Therapeutics
Safety
Endometritis
Pelvic Inflammatory Disease
Aerobic Bacteria
Bacteroides
Anaerobic Bacteria
Neisseria gonorrhoeae
Multicenter Studies
Signs and Symptoms
Escherichia coli
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Poindexter, A. N., Ritter, M., Faro, S., Castellano, M. A., Gentry, L. O., Ismail, M., ... Sweet, R. L. (1988). Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology, 158(3 II SUPPL.), 717-721.

Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. / Poindexter, A. N.; Ritter, M.; Faro, S.; Castellano, M. A.; Gentry, L. O.; Ismail, M.; Knuppel, R. A.; Kreutner, A. K.; Lamb, E. J.; LeFrock, J. L.; Miller, R. D.; Naftolin, F.; Sweet, Richard L.

In: American Journal of Obstetrics and Gynecology, Vol. 158, No. 3 II SUPPL., 1988, p. 717-721.

Research output: Contribution to journalArticle

Poindexter, AN, Ritter, M, Faro, S, Castellano, MA, Gentry, LO, Ismail, M, Knuppel, RA, Kreutner, AK, Lamb, EJ, LeFrock, JL, Miller, RD, Naftolin, F & Sweet, RL 1988, 'Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections', American Journal of Obstetrics and Gynecology, vol. 158, no. 3 II SUPPL., pp. 717-721.
Poindexter AN, Ritter M, Faro S, Castellano MA, Gentry LO, Ismail M et al. Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology. 1988;158(3 II SUPPL.):717-721.
Poindexter, A. N. ; Ritter, M. ; Faro, S. ; Castellano, M. A. ; Gentry, L. O. ; Ismail, M. ; Knuppel, R. A. ; Kreutner, A. K. ; Lamb, E. J. ; LeFrock, J. L. ; Miller, R. D. ; Naftolin, F. ; Sweet, Richard L. / Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections. In: American Journal of Obstetrics and Gynecology. 1988 ; Vol. 158, No. 3 II SUPPL. pp. 717-721.
@article{802d58f8be314597ae16d6325a6aeff1,
title = "Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections",
abstract = "In a multicenter trial involving 11 centers, 160 women were enrolled to evaluate the safety and effectiveness of 1 or 2 gm of cefotetan administered every 12 hours in the treatment of obstetric and gynecologic infections. The 133 evaluable patients generally were under 25 years of age, were nonwhite, and had hospital acquired endometritis or pelvic inflammatory disease caused by both aerobic and anaerobic bacteria. Escherichia coli, Neisseria gonorrhoeae, group D streptrococci, Bacteroides sp., and Peptococcus sp. were among the most frequently isolated pathogens. The patients were treated for a mean of 5.6 ± 1.6 days and received a total dose of 19.27 gm. The signs and symptoms of infection were cleared or improved in 93{\%} of the 133 patients evaluable for clinical response. Of the 116 evaluated bacteriologically, 95{\%} had a satisfactory or presumed satisfactory response; only six patients (5{\%}) were considered to be bacteriologic failures. Differences in the results of several clinical laboratory tests performed before and after treatment were statistically, but not clinically, significant (p < 0.05). Safety was evaluated in the 158 patients who received cefotetan, and only four (3{\%}) had adverse reactions considered related to the drug. Cefotetan was clearly effective and produced no untoward reactions in these women with obstetric and gynecologic infections caused by both aerobic and anaerobic organisms when administered at 1 or 2 gm every 12 hours.",
author = "Poindexter, {A. N.} and M. Ritter and S. Faro and Castellano, {M. A.} and Gentry, {L. O.} and M. Ismail and Knuppel, {R. A.} and Kreutner, {A. K.} and Lamb, {E. J.} and LeFrock, {J. L.} and Miller, {R. D.} and F. Naftolin and Sweet, {Richard L}",
year = "1988",
language = "English (US)",
volume = "158",
pages = "717--721",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3 II SUPPL.",

}

TY - JOUR

T1 - Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections

AU - Poindexter, A. N.

AU - Ritter, M.

AU - Faro, S.

AU - Castellano, M. A.

AU - Gentry, L. O.

AU - Ismail, M.

AU - Knuppel, R. A.

AU - Kreutner, A. K.

AU - Lamb, E. J.

AU - LeFrock, J. L.

AU - Miller, R. D.

AU - Naftolin, F.

AU - Sweet, Richard L

PY - 1988

Y1 - 1988

N2 - In a multicenter trial involving 11 centers, 160 women were enrolled to evaluate the safety and effectiveness of 1 or 2 gm of cefotetan administered every 12 hours in the treatment of obstetric and gynecologic infections. The 133 evaluable patients generally were under 25 years of age, were nonwhite, and had hospital acquired endometritis or pelvic inflammatory disease caused by both aerobic and anaerobic bacteria. Escherichia coli, Neisseria gonorrhoeae, group D streptrococci, Bacteroides sp., and Peptococcus sp. were among the most frequently isolated pathogens. The patients were treated for a mean of 5.6 ± 1.6 days and received a total dose of 19.27 gm. The signs and symptoms of infection were cleared or improved in 93% of the 133 patients evaluable for clinical response. Of the 116 evaluated bacteriologically, 95% had a satisfactory or presumed satisfactory response; only six patients (5%) were considered to be bacteriologic failures. Differences in the results of several clinical laboratory tests performed before and after treatment were statistically, but not clinically, significant (p < 0.05). Safety was evaluated in the 158 patients who received cefotetan, and only four (3%) had adverse reactions considered related to the drug. Cefotetan was clearly effective and produced no untoward reactions in these women with obstetric and gynecologic infections caused by both aerobic and anaerobic organisms when administered at 1 or 2 gm every 12 hours.

AB - In a multicenter trial involving 11 centers, 160 women were enrolled to evaluate the safety and effectiveness of 1 or 2 gm of cefotetan administered every 12 hours in the treatment of obstetric and gynecologic infections. The 133 evaluable patients generally were under 25 years of age, were nonwhite, and had hospital acquired endometritis or pelvic inflammatory disease caused by both aerobic and anaerobic bacteria. Escherichia coli, Neisseria gonorrhoeae, group D streptrococci, Bacteroides sp., and Peptococcus sp. were among the most frequently isolated pathogens. The patients were treated for a mean of 5.6 ± 1.6 days and received a total dose of 19.27 gm. The signs and symptoms of infection were cleared or improved in 93% of the 133 patients evaluable for clinical response. Of the 116 evaluated bacteriologically, 95% had a satisfactory or presumed satisfactory response; only six patients (5%) were considered to be bacteriologic failures. Differences in the results of several clinical laboratory tests performed before and after treatment were statistically, but not clinically, significant (p < 0.05). Safety was evaluated in the 158 patients who received cefotetan, and only four (3%) had adverse reactions considered related to the drug. Cefotetan was clearly effective and produced no untoward reactions in these women with obstetric and gynecologic infections caused by both aerobic and anaerobic organisms when administered at 1 or 2 gm every 12 hours.

UR - http://www.scopus.com/inward/record.url?scp=0023829966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023829966&partnerID=8YFLogxK

M3 - Article

VL - 158

SP - 717

EP - 721

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3 II SUPPL.

ER -